XBiotech Inc. (NASDAQ:XBIT) Short Interest Update

XBiotech Inc. (NASDAQ:XBIT) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 907,400 shares, a growth of 15.2% from the January 15th total of 787,900 shares. Based on an average daily volume of 71,300 shares, the days-to-cover ratio is currently 12.7 days. Approximately 4.7% of the shares of the stock are short sold.

XBiotech Stock Performance

NASDAQ:XBIT opened at $3.27 on Friday. XBiotech has a one year low of $3.05 and a one year high of $9.96. The stock has a market cap of $99.67 million, a PE ratio of -3.03 and a beta of 1.45. The stock has a 50 day moving average price of $4.36 and a 200 day moving average price of $6.03.

Institutional Investors Weigh In On XBiotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in XBiotech by 5.1% in the third quarter. Geode Capital Management LLC now owns 452,264 shares of the biopharmaceutical company’s stock valued at $3,496,000 after purchasing an additional 22,059 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of XBiotech by 2.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,770 shares of the biopharmaceutical company’s stock worth $1,962,000 after purchasing an additional 5,500 shares in the last quarter. State Street Corp increased its position in shares of XBiotech by 10.7% during the third quarter. State Street Corp now owns 224,595 shares of the biopharmaceutical company’s stock worth $1,736,000 after purchasing an additional 21,752 shares in the last quarter. Northern Trust Corp increased its position in shares of XBiotech by 15.2% during the fourth quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company’s stock worth $835,000 after purchasing an additional 27,909 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of XBiotech by 7.5% during the fourth quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 6,328 shares in the last quarter. Institutional investors and hedge funds own 55.70% of the company’s stock.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.